Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers

Inclusion Criteria: * Healthy male and female volunteers * 30 - 70 years (extremes included) * Medical history without any study relevant pathological findings * Written and signed informed consent Exclusion Criteria: * Clinically study relevant acute or chronic disorders, that can be detected by clinical investigation or medical history * Clinical, study-relevant pathological findings of clinical oar laboratory investigations * Clinically relevant pathological EEG findings (e.g. artefact-free parts in Screening-EEG \<30% in one recording * Clinically relevant allergies * positive alcohol testing on Screening, Day A, B, or C, or anamnestic * positive drug screening test on Screening, Day A, B, or C, or anamnestic * Intake of study relevant medication 14 days prior to active Day A, or during active study duration, based on the volunteer´s information * Regular intake of drug with primary central nervous effects (e.g. psychoactive drugs or central acting antihypertensive drugs) * Known hypersensitivity / allergy against herbal extracts (i.e. dry extracts of Passionflower herb, St. John´s Wort herb, Valerian root) or lactose or an other excipient of the investigational medication * Lapp-lactase deficiency (anamnestic) * Hypersensitivity of the skin (anamnestic) * BMI (Body-Mass-Index) \<18 or\>30 * Abuse of caffeine, teeine, or tobacco * Smoking in the investigational site on Day A, B, or C * Participation in an other clinical study within 60 days prior to Screening * Positive Pregnancy Test (on Screening, Day A, B, or C) or Lactation * Bad compliance * Revocation of informed consent